Biotechnology company MabCure, Inc. (OTCBB: MBCI) today announced that it has signed a collaboration agreement with Catholic University, K.U. Leuven and University Hospital, UZ Leuven, Belgium, together comprising one of the largest and most reputable medical centers in Europe.

The agreement reflects the parties’ continued interest in exploring the utility of MabCure’s diagnostic test for ovarian cancer and will assist MabCure in advancing its clinical program. This collaboration follows MabCure’s joint study with Professor Ignace Vergote, a world renowned authority on ovarian cancer, which provided a proof of concept for the ability of MabCure’s antibodies to distinguish between ovarian cancer and benign tumors.

In that study, several of MabCure’s ovarian cancer monoclonal antibodies (MAbs) were tested against 54 different blood samples comprised of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young females and 8 males. Each of the company's proprietary MAbs successfully identified ovarian cancer in blood with 94 percent accuracy (i.e. correctly identifying 16 of 17 patients as having ovarian cancer) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood.

The new collaboration is aimed at expanding MabCure’s diagnostic database in order to pave the way to multi-center clinical studies in Europe and the United States.

Professor Ignace Vergote serves as Chairman of the Multidiciplinary Department of Gynecologic Oncology, University Hospital Leuven, Belgium and Professor of Gynecologic Oncology, Catholic University Leuven, Belgium. From 1997 to 2003 Professor Vergote served as the Chairman of the European Organization for Research and Treatment of Cancer (EORTC), Gynecologic Cancer Group, and is currently the Chairman of the Protocol committee of that group.

Dr. Amnon Gonenne, CEO of MabCure, noted: “we are privileged to form such an important alliance with Professor Vergote and the University Hospital, UZ Leuven. Professor Vergote’s vast knowledge and reputation in the field of gynecological cancers will be invaluable in assisting MabCure during our clinical trials of ovarian cancer and ultimately in reaching a broad network of medical centers in Europe and the U.S.”

About Ovarian Cancer

Each year, 230,000 women worldwide are diagnosed with ovarian cancer, or cancer that forms in the tissues of the ovary, accounting for three percent of cancers in women. More than 125,000 women die from ovarian cancer annually, making it the fifth leading cause of cancer death in women and the deadliest of all gynecological cancers.

About MabCure’s Technology

MabCure has re-engineered classic hybridoma technology. Classic hybridoma technology is based on the generation of immortal hybrid cells or hybridoma, which follows the fusion of antibody-producing B-cells with myeloma tumor cells. Each hybridoma continuously manufactures a single monoclonal antibody. MabCure’s enhanced technology has improved upon this process by increasing MAb yield, improving production times exponentially, and enhancing specificity.

MabCure has successfully generated several highly specific monoclonal antibodies against four different cancers - ovarian cancer, an aggressive form of prostate cancer, colon carcinoma and melanoma. Each of these antibodies has been shown to be "universal" to each type of cancer, i.e. they recognize cancer cells or antigens from different individuals having that particular disease but do not recognize other cancers or normal antigen tested so far. These MAbs are the first candidates for the development of novel diagnostic tools, imaging agents and drugs to treat the corresponding cancers.

About MabCure

MabCure is a U.S. biotechnology company whose mission is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which the company plans to develop as diagnostic tools, imaging agents and therapeutic drugs to treat lethal cancers. The company’s initial focus is on the development of novel diagnostic tests for the early detection of ovarian, prostate, and colorectal cancers, each with multi-billion dollar global market potential. MabCure is also currently exploring the potential of its anti-melanoma antibodies for the development of imaging and therapeutic agents. The company is headquartered in Hasselt, Belgium. For more information about MabCure and to sign up for e-mail updates, visit www.mabcure.com.

This news release contains “forward-looking statements.” Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas MabCure (CE).
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas MabCure (CE).